102 results about "Pancreatic tissue" patented technology

The invention discloses a natural product-based nano antioxidant for treating acute pancreatitis and a preparation method of the natural product-based nano antioxidant, and relates to the technical field of biological medicines. 25 mg of ferulic acid (FA); and 15 mL of 80% (v / v) ethanol-deionized water solution. According to the natural product-based nano antioxidant for treating acute pancreatitis and the preparation method thereof, the nano antioxidant effectively targets inflammatory pancreatic tissues through the specific interaction of chondroitin sulfate (CS) and CD44, and is split and released under the stimulation of pH / GSH and H2O2 in cells to generate FA and zein degradation products, the FA and zein degradation products efficiently play a synergistic role in removing ROS, and the natural product-based nano antioxidant can be used for treating acute pancreatitis. Therefore, inflammation is relieved; the nano antioxidant shows an excellent in-vivo treatment effect on acute pancreatitis and has a clinical application prospect.

The disclosure provides methods and compositions for treating metabolic disorders, including Type 2 Diabetes, obesity, Metabolic Dysfunction-associated Steatotic Liver Disease, and other obesity-related metabolic disorders by combining localized delivery of a gene therapy to pancreatic tissue.

The invention belongs to the field of biological medicines, and discloses application of flufenidone in preparation of a medicine for treating pancreatic diseases. Researches find that the flufenidone can improve serum amylase and lipase levels of an acute pancreatitis model mouse, and can improve pancreatic tissue edema, necrosis and inflammatory cell infiltration of the acute pancreatitis model mouse; the traditional Chinese medicine composition can improve acute pancreatitis model mouse lung tissue alveolar interval thickening and inflammatory cell infiltration, and provides guarantee for application of the traditional Chinese medicine composition in preparation of drugs for treating pancreatic diseases.

The invention belongs to the technical field of microorganisms, and particularly relates to a lactobacillus mucus fermentation TY-M26 and application of the lactobacillus mucus fermentation TY-M26, and the preservation number of the lactobacillus mucus fermentation TY-M26 is CGMCC (China General Microbiological Culture Collection Center) No. 32238. The lactobacillus mucilaginosus TY-M26 has high inhibitory activity on alpha-glucosidase activity, and animal experiments prove that the lactobacillus mucilaginosus TY-M26 can significantly relieve diabetes characteristics of mice with type II diabetes, significantly reduce fasting blood-glucose level, significantly improve insulin resistance and serum insulin level, significantly reduce serum Glu level and serum TG level, and can be used for preparing medicines for treating diabetes mellitus. The pathological injury of pancreatic tissues is obviously improved; the lactobacillus mucilaginosus TY-M26 has the advantages that the lactobacillus mucilaginosus TY-M26 can be used for preparing the lactobacillus mucilaginosus TY-M26, the serum ALT level and the serum AST level can be obviously reduced, the pathological injury of liver tissues can be obviously improved, a certain protection effect on the liver is achieved, and the lactobacillus

The invention discloses an application of astaxanthin in preparation of a regulator for improving the gentisic acid level. On the basis of non-targeted metabonomics analysis, it is found for the first time that in the SAP pathogenesis process, the level of a flora metabolite, namely gentisic acid (GA), in intestinal contents is remarkably reduced, and in-vivo gentisic acid level can be remarkably callback through astaxanthin intervention. Further research proves that exogenous supplement of gentisic acid can effectively simulate the protection effect of astaxanthin, including improvement of pancreatic tissue pathological damage, reduction of serum lipase and amylase activity, and inhibition of systemic inflammatory response (down-regulation of IL-1beta, IL-6 and TNF-alpha and up-regulation of IL-10). The invention not only discloses a new mechanism that astaxanthin plays a therapeutic role through an'intestinal flora-metabolite 'axis, but also determines that gentisic acid is used as a novel drug target for treating SAP, and constructs a new method for screening drugs for treating SAP according to the novel drug target.

The invention discloses a pancreas strapping tape capable of quantifying strapping pressure, and belongs to the technical field of medical instruments, the pancreas strapping tape comprises a first non-extension section and a second non-extension section, an elastic section and a limiting rope are arranged between the first non-extension section and the second non-extension section, and an insertion hole is formed in the head end of the first non-extension section. The quantitative binding force is provided for the pancreatic stump, sufficient bursting pressure can be provided for the main pancreatic duct, complete pancreatic ischemia and acute pancreatic necrosis caused by too high binding pressure are avoided, and the risk of pancreatic fistula and pancreatitis caused by acute pancreatic necrosis is reduced; due to the design of the limiting rope, whether preset binding tension is reached or not can be easily judged in the binding process; when pancreatic tissue is shrunk in the postoperative process, the strapping tape can still continue to provide strapping pressure through contraction of the elastic section, the strapping pressure generated in the postoperative process is reduced in a limited mode, enough bursting pressure can still be provided for the main pancreatic duct, and the risk of pancreatic fistula caused by insufficient bursting pressure of the main pancreatic duct is reduced.

The present application relates to a deoxyribonuclease mutant and its application in preparing PDRN. The amino acid sequence of the deoxyribonuclease mutant is shown as SEQ ID NO. 1, and the nucleotide sequence of the encoding gene is shown as SEQ ID NO. 2. The present application also provides the application of the deoxyribonuclease mutant and / or the encoding gene of the deoxyribonuclease mutant in preparing PDRN, and the specific application method. The present application is based on the deoxyribonuclease expressed by the DNASE1 gene of bovine pancreas tissue, and the amino acids at positions 69, 132 and 215 are selected for iterative saturation mutation. Compared with the wild-type enzyme, the enzyme activity of the deoxyribonuclease mutant A69H-S132R-Q215C is increased by 2.15 times, reaching 4.1x10 6 U / mL, and the DNA extraction rate of salmon PDRN prepared by using the mutant enzyme prepared by the present application is 15.2%, the DNA content is 99.1%, and the molecular weight is 1.05 million Daltons, which is significantly improved compared with the wild-type enzyme, and the PDRN in this molecular weight range has more significant biological activity.

The invention discloses a method for constructing a diabetes animal model after hyperlipidemia type acute pancreatitis. The method comprises the following steps: S1, selecting male C57BL / 6N mice which are 7 weeks old, and feeding the male C57BL / 6N mice with hyperlipidemia; s2, injecting froglein into the abdominal cavity of the hyperlipemia mouse; s3, replacing drinking water of the mice with 5% sweet water, and testing fasting blood glucose and random blood glucose on the first day, the fourth day and the seventh day after the rain frog element is injected; s4, when the random blood glucose of the mouse is larger than or equal to 16.7 mmol / L or the fasting blood glucose of the mouse is larger than or equal to 11.1 mmol / L, the mouse And S5, killing the mouse with cervical vertebra dislocation, taking pancreatic tissues of the mouse, fixing the pancreatic tissues, performing HE staining, and if an acinus structure is damaged, cells are swelled and necrotic and a large number of inflammatory cells of interstitial substances are infiltrated, judging that the acute pancreatitis is molded. Meanwhile, if the conditions are met, it can be judged that the mouse is a diabetic mouse after hyperlipidemia type acute pancreatitis. The method can simulate the occurrence of diabetes mellitus after hyperlipemia type acute pancreatitis, and lays a good foundation for the research of diabetes mellitus after hyperlipemia type acute pancreatitis.

The invention discloses a preparation rich in polygonatum sibiricum polypeptide and application of the preparation in diabetes mellitus. The composition is prepared from rhizoma polygonati polypeptide, semeglutide, astaxanthin, an active agent and a ferroptosis mixture. Pharmacodynamic experiments show that in a diabetic mouse model, fasting blood glucose can be remarkably reduced, the serum insulin level can be increased, renal function indexes can be improved, and expression of NLRP3 inflammation pathway related proteins (NLRP3, Caspase-1 and IL-1beta) in pancreatic tissue can be remarkably inhibited. By integrating multiple mechanisms of blood glucose reduction, oxidation resistance, inflammation resistance, ferroptosis resistance and the like, multi-target collaborative intervention is realized, the pharmaceutical composition is remarkably superior to a single component in the aspects of blood glucose reduction, pancreas islet function protection and complication alleviation, and a new clinical strategy is provided for treatment of diabetes mellitus, especially type 1 diabetes mellitus.

The invention discloses a Ruditapes philippinarum miR-263b inhibitor and application thereof, and finds that Ruditapes philippinarum miR-263b can regulate and control innate immune response of a host by targeting RpSC2, negatively regulates activation of an immune-related signal channel in a vibrio infection process, and further, on the basis of a molecular regulation and control mechanism, the Ruditapes philippinarum miR-263b inhibitor can be used for inhibiting the infection of vibrio. The invention discloses a specific inhibitor which is completely complementary with a miR-263b mature body sequence. Experimental data show that after Ruditapes philippinarum is injected with the miR-263b inhibitor, the expression level of miR-263b in vivo is reduced, and the inhibition effect of miR-263b on RpSC2 is effectively relieved, so that the expression level of a target gene RpSC2 is up-regulated, an NF-kappa B immune signal channel is activated, the immune defense capability of the Ruditapes philippinarum on vibrio anguillarum is enhanced, the death rate after infection is remarkably reduced, and the Ruditapes philippinarum is prevented from being infected. The in-vivo bacterium loading amount is obviously reduced, and the pathological injury of hepatopancreas tissue is obviously relieved.

Systems and methods are provided for delivering a therapeutic treatment to a target population of cells (including, but not limited to, tumors, eyeballs, pancreatic tissue, liver tissue, and lung tissue) in a subject. The system includes an injectable aqueous solution in a vial enclosed with a septum. The solution comprises particles containing a therapeutic agent and having a coating surrounding the therapeutic agent, the coating comprising chitosan to provide controlled release of the agent from the particles. The solution also comprises a chitosan polymer in the form of a polymer gel matrix, further providing controlled release of the particles from the aqueous gel environment. There is also provided a method of making a freeze-dried powder placed in a vial containing a chitosan polymer and chitosan-coated particles, the powder when mixed with water forming the above injectable aqueous solution with particles and chitosan gel.

The invention provides an application of dimethyl fumarate in preparation of a medicine for treating hypertriglyceridemia type acute pancreatitis. Experiments prove that the dimethyl fumarate can treat the hypertriglyceridemia acute pancreatitis, and specifically, the dimethyl fumarate can relieve pancreatic tissue edema of the hypertriglyceridemia acute pancreatitis, relieve pancreatitis infiltration, relieve pancreatic acinus necrosis and the like. The invention provides a new strategy for treating hypertriglyceridemia acute pancreatitis, and has a good clinical application prospect.

The invention discloses a probiotic agent for relieving prediabetic action and application thereof, and belongs to the technical field of microorganisms. Experiments prove that bifidobacterium longum CCFM1113 and bifidobacterium adolescentis CCFM1386 composite probiotics can relieve the prediabetic stage, which is specifically embodied in reducing weight gain of mice in the prediabetic stage, regulating blood sugar metabolism, improving sugar tolerance and insulin resistance, protecting liver and pancreas tissues, being beneficial to increasing the diversity of intestinal flora, recovering the structure of the intestinal flora, and improving the immunity of the mice in the prediabetic stage. The invention also provides a preparation method of the bifidobacterium longum CCFM1113 and bifidobacterium adolescentis CCFM1386 composite probiotics. The bifidobacterium longum CCFM1113 and bifidobacterium adolescentis CCFM1386 composite probiotics. And the growth of beneficial bacteria related to metabolic disorder is enriched and regulated. The invention provides an important basis for developing a dietary formula suitable for prediabetic patients, and provides a new method for prevention and management of diabetes mellitus.

The invention relates to the technical field of novel application of compounds, in particular to novel application of meclozine and analogues thereof. The invention relates to an application of at least one of meclozine and analogues thereof or pharmaceutically acceptable salts or esters thereof in preparation of drugs for preventing and / or treating pancreatitis. The meclozine and the analogue thereof can obviously improve pancreatic tissue necrosis, inflammatory response and oxidative stress of pancreatitis, inhibit alveolar cell death and improve lung injury caused by pancreatitis, so that the meclozine and the analogue thereof can be used as a medicine for treating pancreatitis.

The invention discloses highly acetylated glucomannan and application thereof in preparation of a product with an effect of relieving prediabetes mellitus, and belongs to the technical field of medicines. In-vivo experiments prove that the glucomannan with high acetylation degree has the effect of relieving the prediabetic stage, which is specifically reflected in weight gain of mice in the prediabetic stage, regulation of blood glucose metabolism, improvement of glucose tolerance and insulin resistance, regulation of blood lipid metabolism, protection of liver and pancreatic tissues and reduction of epididymal fat cell size. The invention provides an important basis for developing a dietary formula suitable for prediabetic patients, and provides a new method for prevention and management of diabetes mellitus.

Methods of using pulsed focused ultrasound (pFUS) therapy to treat pancreatic disorders such as type 1 diabetes, pancreatitis, and pancreatic cancer are provided. The methods utilize pulsed focused ultrasound (pFUS) therapy either by itself or in combination with islet transplantation and / or stem cell therapy to promote regeneration of damaged pancreatic tissue, increase insulin secretion in response to glucose, or improve engraftment and revascularization of transplanted islets or beta cells. Additionally, methods of using pFUS are provided for modulating paracrine secretion in the pancreas, islets, beta cells, or stem cells, or at a transplantation site to therapeutically alter levels of various factors including, without limitation, cytokines, growth factors, angiogenic factors, and cell adhesion molecules.

To provide various compositions and methods useful for the treatment of pancreatic cancer, such as pancreatic ductal adenocarcinoma (PDAC), and methods for activating pancreatic tissue-specific anti-tumor T cell immunity.SOLUTION: In certain embodiments, such methods comprise administration of IL33. In certain embodiments, such methods comprise administration of PD-1 and / or PD - L1 inhibitors.SELECTED DRAWING: None

According to the invention, GWAS analysis is carried out on immune traits of Qingyuan partridge chicken infected with ALV-J, and SNP molecular markers related to immune traits such as spleen tissue index, pancreatic tissue index, IL-6 content in blood, IFN-beta content in blood and cloaca virus positive degree are screened and obtained; the SNP molecular markers can be applied to disease-resistant molecular marker assisted breeding of Qingyuan partridge chickens. Through molecular marker-assisted breeding, the spleen tissue index, the pancreatic tissue index, the IL-6 content and the IFN-beta content in blood of the Qingyuan partridge chicken can be increased, especially the IL-6 content and the IFN-beta content in the blood infected with ALV-J can be increased, the ALV-J infection resistance of the chicken is improved, and the immunity of the chicken is improved. Meanwhile, breeding is assisted through the molecular marker, the cloaca virus positive degree of the chickens infected with ALV-J can be reduced, the diseases infected with ALV-J and the ALV-J infection resisting capacity are relieved, and the immunity of the chickens is improved. Therefore, the medicine use cost of the chicken farm is reduced, the economic performance of the chicken farm is improved, and healthy breeding is promoted.

The present invention belongs to the field of biological medicine technology, and relates to a new application of daptomycin, specifically the application of daptomycin in the preparation of drugs for treating or preventing chronic pancreatitis. Daptomycin can inhibit macrophage M2 polarization, reduce pancreatic fibrosis caused by chronic pancreatitis, and reduce pancreatic tissue changes caused by chronic pancreatitis. The present invention may provide an effective prodrug for the prevention and treatment of chronic pancreatitis.

The invention belongs to the technical field of bacterial strain application, and particularly relates to application of bifidobacterium lactis TY-S01 or a product thereof in preparation of a preparation for preventing or improving or treating diabetes. Animal experiments prove that the bifidobacterium lactis TY-S01 can obviously relieve diabetes characteristics (weight loss and water intake increase) of type II diabetic mice, obviously reduce fasting blood-glucose level, obviously improve insulin resistance and serum insulin level, obviously reduce serum glycosylated hemoglobin A1c level, serum Glu level and serum TG level, and can obviously inhibit the diabetes mellitus of the type II diabetic mice, so that the bifidobacterium lactis TY-S01 can be used for treating diabetes mellitus of the type II diabetic mice. The pathological injury of pancreatic tissues is obviously improved; the serum ALT level and the serum AST level can be obviously reduced, the pathological injury of liver tissues is obviously improved, and a certain protection effect is achieved on the liver.

The development of devices for a functional cure for diabetes by mimicking native pancreatic tissue for production of all pancreatic hormones. A physiologically and mechanically biocompatible artificial pancreas, wherein the pancreas comprises a combination of a PVA hydrogel combined with cells selected from the group consisting of islets; clusters of islets; Beta cells, and combinations of islets and Beta cells. The bioartificial pancreas contains vascular grafts therein or thereon a wall of the pancreas so that said grafts are an integral part of the wall of the bioartificial pancreas. The grafts can be anasmotized to living blood vessels in the body.

This invention belongs to the field of biomedical technology and discloses the application of NP in the preparation of a glycemic regulator for aging type 2 diabetes. The NP is a nanoscale complex formed by hydrogen bonding of turtle egg peptide with a molecular weight less than 3 kDa and naringenin at a mass ratio of 100:1. The formulation promotes liver glycogen synthesis and repairs pancreatic tissue structure and pancreatic β-cell function by activating the hepatic IRS1 / PI3K / AKT / GSK-3β signaling pathway and upregulating GLUT2 protein expression. The NP provided by this invention can significantly reduce fasting blood glucose levels in aging type 2 diabetic mice, improve oral glucose tolerance, and reduce the area under the blood glucose curve. Simultaneously, by restoring insulin signal transduction, it significantly reduces the insulin resistance index and improves the insulin sensitivity index, with an improvement level approaching that of the classic hypoglycemic drug metformin.

The present invention discloses the preparation of Sipunculus nudus hypoglycemic peptide and its application in the preparation of drugs for regulating blood glucose and blood lipids in type 2 diabetes, belonging to the field of biomedical technology. The Sipunculus nudus polypeptide provided by the present invention can significantly reduce the blood glucose concentration of T2DM, regulate the level of insulin resistance, inhibit the levels of triglyceride and low-density lipoprotein cholesterol in the serum of T2DM, increase the level of high-density lipoprotein cholesterol, and at the same time has a protective effect on the pathological changes of pancreatic tissue. In addition, administration of Sipunculus nudus polypeptide can increase the activity of SOD in the serum and inhibit the expression of malondialdehyde, a lipid peroxidation marker. The Sipunculus nudus polypeptide can significantly improve the abnormal blood glucose and blood lipids in type 2 diabetes, and has no toxicity or side effects on animals and will not accumulate in animals. Therefore, the Sipunculus nudus polypeptide can be used to prepare drugs or foods for regulating blood glucose and blood lipids in type 2 diabetes.

The invention belongs to the field of pancreatic duct adenocarcinoma prediction, and provides a pancreatic duct adenocarcinoma prediction method and system based on oral flora. The pancreatic ductal adenocarcinoma prediction method based on oral flora comprises the following steps: acquiring relative abundance information of each biomarker in a potential biomarker set for diagnosing pancreatic ductal adenocarcinoma of a to-be-detected person; using the relative abundance information of each biomarker in the biomarker set and a pre-trained multivariate statistical model to obtain a probability value of suffering from pancreatic ductal adenocarcinoma; the method comprises the following steps: performing microbiome difference analysis on saliva, duodenal juice and pancreatic tissue samples of a pancreatic ductal adenocarcinoma patient group and a pancreatic benign disease patient group, and taking an intersection of differential bacteria in the samples to obtain a potential biomarker set for diagnosing the pancreatic ductal adenocarcinoma.

The invention discloses application of pancreatic protein peptide in preparation of products for improving insulin resistance and repairing pancreatic functions, and relates to the technical field of biological medicines. The pancreatic-derived protein peptide is extracted and purified from porcine pancreatic tissue through a specific enzymolysis process, the molecular weight is concentrated at 800-2000Da, and the pancreatic-derived protein peptide contains 12 essential amino acids. Experiments prove that the protein peptide can significantly improve insulin sensitivity and promote pancreatic beta cell proliferation through oral administration or intraperitoneal injection, and has no obvious toxic or side effect. The invention provides a novel treatment means for diseases related to type 2 diabetes and pancreatic function impairment, and has a wide clinical application prospect.

Disclosed herein are hepato-biliary-pancreatic organoid (“HBPO” or “HBP organoid”) compositions, and methods of making and using hepato-biliary-pancreatic organoid compositions. The disclosed compositions may have two or more functions selected from hepatic tissue function, biliary tissue function, exocrine pancreatic function, and endocrine pancreatic tissue function. Methods of treating individuals using the hepato-biliary-pancreatic organoid compositions is also disclosed.

To provide systems and methods for delivering a therapeutic treatment to a targeted population of cells of a subject.SOLUTION: The system includes an injectable aqueous solution in a vial enclosed with a septum. The injectable aqueous solution is formulated for injection into a targeted cell population. The solution includes particles containing a therapeutic agent and having a coating around the therapeutic agent, the coating including chitosan so as to provide controlled release of the agent from the particles. The solution further includes chitosan polymer in a form of a polymer gel matrix, further providing controlled release of the particles from the aqueous gel environment. Also provided are methods of manufacturing a lyophilized powder disposed within a vial containing chitosan polymer and chitosan coated particles, the powder forming the above-described injectable aqueous solution of particles and chitosan gel upon mixing with water. Also provided are methods of injecting the above-described injectable aqueous solution into a targeted population of cells, including but not limited to tumors, eyeballs, pancreatic tissue, liver tissue, and lung tissue, in order to provide localized delivery of a therapeutic agent.SELECTED DRAWING: Figure 12

The invention discloses an application of sgRNA targeting PGAM5 in acute pancreatitis as well as a product and a gene therapy drug of the sgRNA. In-vivo experiments prove that the PGAM5-targeted sgRNA can significantly inhibit PGAM5 gene expression, reduce pancreatic tissue inflammatory cell infiltration and reduce serum lipase and amylase levels, thereby blocking generation and development of AP. According to the invention, the targeted knockout of the PGAM5 gene by using the CRISPR-Cas9 system is proposed for the first time, and a new strategy is provided for the gene therapy of AP.

The present disclosure relates to a medical tissue adhesive for pancreatic plugging and the preparation method and use thereof. The medical tissue adhesive composition forming the medical tissue adhesive of the present disclosure comprises a medical tissue adhesive component and a chelating agent component; wherein the medical tissue adhesive component comprises a first component and a second component, the first component comprises four-arm polyethylene glycol amine, and the second component comprises four-arm-polyethylene glycol-succinimidyl glutarate; wherein m and n are natural numbers; and the chelating agent component comprises polyphenol. The medical tissue adhesive prepared from the medical tissue adhesive composition of the present disclosure is capable of firmly binding to the surface of the pancreatic tissue, and is capable of withstanding the dynamic pressure as a result of pancreatic juice leakage and the enzymatic degradation activity of pancreatic juice. More importantly, the medical tissue adhesive of the present disclosure has an excellent antibacterial ability and is capable of preventing the infection caused by the long-term accumulation of the leaked pancreatic juice.